Deutsche Märkte geschlossen

NexImmune, Inc. (NEXI)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
3,93000,0000 (0,00%)
Börsenschluss: 04:00PM EDT
3,4500 -0,48 (-12,21%)
Nachbörse: 07:59PM EDT

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter6

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Ms. Kristi Jones R.Ph.CEO, President & Director989,28kN/A1963
Dr. Mathias Oelke Ph.D.Chief Scientific Officer605,78kN/A1968
Mr. John Trainer M.B.A.Consultant1,33MN/A1974
Mr. Albert Nicholas Marchio IIInterim CFO & Principal Accounting OfficerN/AN/A1952
Ms. Karen HaslbeckHead of Human ResourcesN/AN/AN/A
Dr. Daniel P. BednarikSenior Vice President of Molecular Engineering & Protein DesignN/AN/AN/A
Dr. Robert Douglas Knight M.D.Chief Medical Officer454,77kN/A1951
Mr. Chad RubinSenior Vice President of Corporate AffairsN/AN/AN/A
Dr. Jack A. Ragheb M.D., Ph.D.Senior Vice President of Translational ScienceN/AN/AN/A
Mr. Matthew SchillerHead of Business DevelopmentN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

NexImmune, Inc.s ISS Governance QualityScore, Stand 1. Juli 2024, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.